Alpha Cognition (ACOG) and Its Rivals Head-To-Head Survey

Alpha Cognition (NASDAQ:ACOG) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Alpha Cognition to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.

Valuation & Earnings

This table compares Alpha Cognition and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-1.98
Alpha Cognition Competitors	$574.62 million	-$70.96 million	0.08

Alpha Cognition’s rivals have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Alpha Cognition and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1931	5389	13958	296	2.58

Alpha Cognition currently has a consensus target price of $20.00, suggesting a potential upside of 293.70%. As a group, “Biological products, except diagnostic” companies have a potential upside of 107.31%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Alpha Cognition is more favorable than its rivals.

Risk and Volatility

Alpha Cognition has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s rivals have a beta of -3.86, meaning that their average share price is 486% less volatile than the S&P 500.

Insider and Institutional Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 31.5% of Alpha Cognition shares are held by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Alpha Cognition and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Summary

Alpha Cognition beats its rivals on 8 of the 13 factors compared.

Alpha Cognition Company Profile

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.